Senti Biosciences, Inc. (SNTI) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.18

From 52W high−92.81%

Volume284078.00

Market cap$5.35M

P/E (TTM)—

P/S (TTM)97.3x

Div yield—

Key dataNov 4, 2026

Open

$0.18

From 52W high

−92.81%

Volume

284078.00

Market cap

$5.35M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

P/E (TTM)

—

RSI (14)

35.2

MomentumView details →

1D Return

−3.37%

YTD Return

−82.74%

SummaryUpdated Jun 1, 2026

Senti Biosciences, Inc. (NASDAQ:SNTI) is a gene circuit company founded in 2016 and headquartered in South San Francisco, California. The company went public in May 2021 and operates in the biotechnology sector, focusing on developing advanced cell and gene therapies. Senti has positioned itself at the intersection of synthetic biology and cancer immunotherapy, utilizing engineered gene circuits to create "smart" therapeutic cells that can make complex biological decisions within the human body.

Ask drillr about Senti Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.4x

EV/Sales

347.6x

P/S (TTM)

97.3x

P/B (TTM)

−1.6x

ProfitabilityView details →

Gross Margin

−2736.36%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

1457.34%

ROA (TTM)

−149.72%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+82.42%

FCF YoY

+21.87%

Revenue CAGR 3Y

−81.15%

EPS CAGR 3Y

+76.24%

EBITDA YoY

−22.04%

MomentumView details →

1D Return

−3.37%

YTD Return

−82.74%

1Y Return

−90.08%

RSI (14)

35.2

vs 50D SMA

−38.35%

vs 200D SMA

−74.92%

Capital & dividendView details →

Debt/Equity

−5.95x

Current Ratio

0.83x

Quick Ratio

0.83x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.41

EPS Surprise

−24.24%

Beats (12Q)

6/12

Next Q EPS Est

−$0.21

Avg Surprise (4Q)

−15.72%

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

55000.00

Net Income (TTM)

−49.56M

Op. CF (TTM)

−38.05M

Next earningsNov 12, 2026 →

Latest newsMore news →

Edward Mathers resigned from the board of directors of Senti Biosciences, Inc.7d ago

Brenda Cooperstone resigned as a member and Chair of the Compensation Committee of the Board of Senti Biosciences Holdings, Inc., effective September 23, 2026.41d ago

Similar companies

Processa Pharmaceuticals, Inc.PCSA Instinct Bio Technical Co. Holdings Inc.BIOT Reviva Pharmaceuticals Holdings, Inc.RVPH Niki BioSolutions, Inc.NIKI Skye Bioscience, Inc.SKYE AlphaTON Capital Corp.ALP Find similar companies →

Latest newsMore news →

Edward Mathers resigned from the board of directors of Senti Biosciences, Inc.7d ago Brenda Cooperstone resigned as a member and Chair of the Compensation Committee of the Board of Senti Biosciences Holdings, Inc., effective September 23, 2026.41d ago